Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab dose-finding trial in sporadic inclusion body myositis
jRCT2080222316Phase 3
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimagrumab in inclusion body myositis (IBM) (4 arms), sponsored by Novartis. Primary endpoints: Physical function at 52 weeks, Muscle strength at 52 weeks and 1 more.
02
Drugs
bimagrumab
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on jRCT2080222316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222316.